A Novel Mechanism Underlying Antiviral Activity of an Influenza Virus M2-Specific Antibody
Protective immunity against influenza A viruses (IAVs) generally depends on antibodies to the major envelope glycoprotein, hemagglutinin (HA), whose antigenicity is distinctive among IAV subtypes. On the other hand, the matrix 2 (M2) protein is antigenically highly conserved and has been studied as...
Gespeichert in:
Veröffentlicht in: | Journal of virology 2020-12, Vol.95 (1) |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 1 |
container_start_page | |
container_title | Journal of virology |
container_volume | 95 |
creator | Manzoor, Rashid Eguchi, Nao Yoshida, Reiko Ozaki, Hiroichi Kondoh, Tatsunari Okuya, Kosuke Miyamoto, Hiroko Takada, Ayato |
description | Protective immunity against influenza A viruses (IAVs) generally depends on antibodies to the major envelope glycoprotein, hemagglutinin (HA), whose antigenicity is distinctive among IAV subtypes. On the other hand, the matrix 2 (M2) protein is antigenically highly conserved and has been studied as an attractive vaccine antigen to confer cross-protective immunity against multiple subtypes of IAVs. However, antiviral mechanisms of M2-specific antibodies are not fully understood. Here, we report the molecular basis of antiviral activity of an M2-specific monoclonal antibody (MAb), rM2ss23. We first found that rM2ss23 inhibited A/Aichi/2/1968 (H3N2) (Aichi) but not A/PR/8/1934 (H1N1) (PR8) replication. rM2ss23 altered the cell surface distribution of M2, likely by cross-linking the molecules, and interfered with the colocalization of HA and M2, resulting in reduced budding of progeny viruses. However, these effects were not observed for another strain, PR8, despite the binding capacity of rM2ss23 to PR8 M2. Interestingly, HA was also involved in the resistance of PR8 to rM2ss23. We also found that two amino acid residues at positions 54 and 57 in the M2 cytoplasmic tail were critical for the insensitivity of PR8 to rM2ss2. These findings suggest that the disruption of the M2-HA colocalization on infected cells and subsequent reduction of virus budding is one of the principal mechanisms of antiviral activity of M2-specific antibodies and that anti-M2 antibody-sensitive and -resistant IAVs have different properties in the interaction between M2 and HA.
Although the IAV HA is the major target of neutralizing antibodies, most of the antibodies are HA subtype specific, restricting the potential of HA-based vaccines. On the contrary, the IAV M2 protein has been studied as a vaccine antigen to confer cross-protective immunity against IAVs with multiple HA subtypes, since M2 is antigenically conserved. Although a number of studies highlight the protective role of anti-HA neutralizing and nonneutralizing antibodies, precise information on the molecular mechanism of action of M2-specific antibodies is still obscure. In this study, we found that an anti-M2 antibody interfered with the HA-M2 association, which is important for efficient budding of progeny virus particles from infected cells. The antiviral activity was IAV strain dependent despite the similar binding capacity of the antibody to M2, and, interestingly, HA was involved in susceptibility to the antibody. Our |
doi_str_mv | 10.1128/jvi.01277-20 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7737731</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2451855692</sourcerecordid><originalsourceid>FETCH-LOGICAL-c537t-7901a1faad9b5e6c7a1b55f4fda0b712a73031e4ffad85a3a7c1d363fbb8480e3</originalsourceid><addsrcrecordid>eNpVkctLAzEQxoMoWh83z5KjB7dmkk2zvQil-Kj4OGhFvITZbKKRbbZudgv1r3fVKgoDMzC_-eZjhpB9YH0Anh2_LnyfAVcq4WyN9IANs0RKSNdJjzHOEymyxy2yHeMrY5Cmg3STbAnBpOQSeuRpRG-qhS3ptTUvGHyc0WkobF0ufXimo9D4ha-xpCPzWTVLWjmKgU6CK1sb3pE--LqN9Jond3NrvPPmayiviuUu2XBYRru3yjtkenZ6P75Irm7PJ-PRVWKkUE2ihgwQHGIxzKUdGIWQS-lSVyDLFXBUggmwqXNYZBIFKgOFGAiX51maMSt2yMm37rzNZ7YwNjSdYz2v_Qzrpa7Q6_-d4F_0c7XQSokuoBM4XAnU1VtrY6NnPhpblhhs1UbNUwmZlIMh79Cjb9TUVYy1db9rgOnPd-jLh4n-eofmrMMP_lr7hX_uLz4AI66Hkw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2451855692</pqid></control><display><type>article</type><title>A Novel Mechanism Underlying Antiviral Activity of an Influenza Virus M2-Specific Antibody</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Manzoor, Rashid ; Eguchi, Nao ; Yoshida, Reiko ; Ozaki, Hiroichi ; Kondoh, Tatsunari ; Okuya, Kosuke ; Miyamoto, Hiroko ; Takada, Ayato</creator><contributor>Heise, Mark T.</contributor><creatorcontrib>Manzoor, Rashid ; Eguchi, Nao ; Yoshida, Reiko ; Ozaki, Hiroichi ; Kondoh, Tatsunari ; Okuya, Kosuke ; Miyamoto, Hiroko ; Takada, Ayato ; Heise, Mark T.</creatorcontrib><description>Protective immunity against influenza A viruses (IAVs) generally depends on antibodies to the major envelope glycoprotein, hemagglutinin (HA), whose antigenicity is distinctive among IAV subtypes. On the other hand, the matrix 2 (M2) protein is antigenically highly conserved and has been studied as an attractive vaccine antigen to confer cross-protective immunity against multiple subtypes of IAVs. However, antiviral mechanisms of M2-specific antibodies are not fully understood. Here, we report the molecular basis of antiviral activity of an M2-specific monoclonal antibody (MAb), rM2ss23. We first found that rM2ss23 inhibited A/Aichi/2/1968 (H3N2) (Aichi) but not A/PR/8/1934 (H1N1) (PR8) replication. rM2ss23 altered the cell surface distribution of M2, likely by cross-linking the molecules, and interfered with the colocalization of HA and M2, resulting in reduced budding of progeny viruses. However, these effects were not observed for another strain, PR8, despite the binding capacity of rM2ss23 to PR8 M2. Interestingly, HA was also involved in the resistance of PR8 to rM2ss23. We also found that two amino acid residues at positions 54 and 57 in the M2 cytoplasmic tail were critical for the insensitivity of PR8 to rM2ss2. These findings suggest that the disruption of the M2-HA colocalization on infected cells and subsequent reduction of virus budding is one of the principal mechanisms of antiviral activity of M2-specific antibodies and that anti-M2 antibody-sensitive and -resistant IAVs have different properties in the interaction between M2 and HA.
Although the IAV HA is the major target of neutralizing antibodies, most of the antibodies are HA subtype specific, restricting the potential of HA-based vaccines. On the contrary, the IAV M2 protein has been studied as a vaccine antigen to confer cross-protective immunity against IAVs with multiple HA subtypes, since M2 is antigenically conserved. Although a number of studies highlight the protective role of anti-HA neutralizing and nonneutralizing antibodies, precise information on the molecular mechanism of action of M2-specific antibodies is still obscure. In this study, we found that an anti-M2 antibody interfered with the HA-M2 association, which is important for efficient budding of progeny virus particles from infected cells. The antiviral activity was IAV strain dependent despite the similar binding capacity of the antibody to M2, and, interestingly, HA was involved in susceptibility to the antibody. Our data provide a novel mechanism underlying antiviral activity of M2-specific antibodies.</description><identifier>ISSN: 0022-538X</identifier><identifier>EISSN: 1098-5514</identifier><identifier>DOI: 10.1128/jvi.01277-20</identifier><identifier>PMID: 33055251</identifier><language>eng</language><publisher>United States: American Society for Microbiology</publisher><subject>Amino Acids ; Animals ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal - metabolism ; Antibodies, Viral - immunology ; Antibodies, Viral - pharmacology ; Antiviral Agents - immunology ; Antiviral Agents - pharmacology ; Dogs ; HEK293 Cells ; Hemagglutinin Glycoproteins, Influenza Virus - metabolism ; Humans ; Influenza A virus - drug effects ; Influenza A virus - genetics ; Influenza A virus - immunology ; Madin Darby Canine Kidney Cells ; Mutation ; Protein Binding - drug effects ; Species Specificity ; Vaccines and Antiviral Agents ; Viral Matrix Proteins - chemistry ; Viral Matrix Proteins - genetics ; Viral Matrix Proteins - immunology ; Viral Matrix Proteins - metabolism ; Virus Release - drug effects</subject><ispartof>Journal of virology, 2020-12, Vol.95 (1)</ispartof><rights>Copyright © 2020 American Society for Microbiology.</rights><rights>Copyright © 2020 American Society for Microbiology. 2020 American Society for Microbiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c537t-7901a1faad9b5e6c7a1b55f4fda0b712a73031e4ffad85a3a7c1d363fbb8480e3</citedby><cites>FETCH-LOGICAL-c537t-7901a1faad9b5e6c7a1b55f4fda0b712a73031e4ffad85a3a7c1d363fbb8480e3</cites><orcidid>0000-0002-7987-9884</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737731/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737731/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33055251$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Heise, Mark T.</contributor><creatorcontrib>Manzoor, Rashid</creatorcontrib><creatorcontrib>Eguchi, Nao</creatorcontrib><creatorcontrib>Yoshida, Reiko</creatorcontrib><creatorcontrib>Ozaki, Hiroichi</creatorcontrib><creatorcontrib>Kondoh, Tatsunari</creatorcontrib><creatorcontrib>Okuya, Kosuke</creatorcontrib><creatorcontrib>Miyamoto, Hiroko</creatorcontrib><creatorcontrib>Takada, Ayato</creatorcontrib><title>A Novel Mechanism Underlying Antiviral Activity of an Influenza Virus M2-Specific Antibody</title><title>Journal of virology</title><addtitle>J Virol</addtitle><description>Protective immunity against influenza A viruses (IAVs) generally depends on antibodies to the major envelope glycoprotein, hemagglutinin (HA), whose antigenicity is distinctive among IAV subtypes. On the other hand, the matrix 2 (M2) protein is antigenically highly conserved and has been studied as an attractive vaccine antigen to confer cross-protective immunity against multiple subtypes of IAVs. However, antiviral mechanisms of M2-specific antibodies are not fully understood. Here, we report the molecular basis of antiviral activity of an M2-specific monoclonal antibody (MAb), rM2ss23. We first found that rM2ss23 inhibited A/Aichi/2/1968 (H3N2) (Aichi) but not A/PR/8/1934 (H1N1) (PR8) replication. rM2ss23 altered the cell surface distribution of M2, likely by cross-linking the molecules, and interfered with the colocalization of HA and M2, resulting in reduced budding of progeny viruses. However, these effects were not observed for another strain, PR8, despite the binding capacity of rM2ss23 to PR8 M2. Interestingly, HA was also involved in the resistance of PR8 to rM2ss23. We also found that two amino acid residues at positions 54 and 57 in the M2 cytoplasmic tail were critical for the insensitivity of PR8 to rM2ss2. These findings suggest that the disruption of the M2-HA colocalization on infected cells and subsequent reduction of virus budding is one of the principal mechanisms of antiviral activity of M2-specific antibodies and that anti-M2 antibody-sensitive and -resistant IAVs have different properties in the interaction between M2 and HA.
Although the IAV HA is the major target of neutralizing antibodies, most of the antibodies are HA subtype specific, restricting the potential of HA-based vaccines. On the contrary, the IAV M2 protein has been studied as a vaccine antigen to confer cross-protective immunity against IAVs with multiple HA subtypes, since M2 is antigenically conserved. Although a number of studies highlight the protective role of anti-HA neutralizing and nonneutralizing antibodies, precise information on the molecular mechanism of action of M2-specific antibodies is still obscure. In this study, we found that an anti-M2 antibody interfered with the HA-M2 association, which is important for efficient budding of progeny virus particles from infected cells. The antiviral activity was IAV strain dependent despite the similar binding capacity of the antibody to M2, and, interestingly, HA was involved in susceptibility to the antibody. Our data provide a novel mechanism underlying antiviral activity of M2-specific antibodies.</description><subject>Amino Acids</subject><subject>Animals</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal - metabolism</subject><subject>Antibodies, Viral - immunology</subject><subject>Antibodies, Viral - pharmacology</subject><subject>Antiviral Agents - immunology</subject><subject>Antiviral Agents - pharmacology</subject><subject>Dogs</subject><subject>HEK293 Cells</subject><subject>Hemagglutinin Glycoproteins, Influenza Virus - metabolism</subject><subject>Humans</subject><subject>Influenza A virus - drug effects</subject><subject>Influenza A virus - genetics</subject><subject>Influenza A virus - immunology</subject><subject>Madin Darby Canine Kidney Cells</subject><subject>Mutation</subject><subject>Protein Binding - drug effects</subject><subject>Species Specificity</subject><subject>Vaccines and Antiviral Agents</subject><subject>Viral Matrix Proteins - chemistry</subject><subject>Viral Matrix Proteins - genetics</subject><subject>Viral Matrix Proteins - immunology</subject><subject>Viral Matrix Proteins - metabolism</subject><subject>Virus Release - drug effects</subject><issn>0022-538X</issn><issn>1098-5514</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkctLAzEQxoMoWh83z5KjB7dmkk2zvQil-Kj4OGhFvITZbKKRbbZudgv1r3fVKgoDMzC_-eZjhpB9YH0Anh2_LnyfAVcq4WyN9IANs0RKSNdJjzHOEymyxy2yHeMrY5Cmg3STbAnBpOQSeuRpRG-qhS3ptTUvGHyc0WkobF0ufXimo9D4ha-xpCPzWTVLWjmKgU6CK1sb3pE--LqN9Jond3NrvPPmayiviuUu2XBYRru3yjtkenZ6P75Irm7PJ-PRVWKkUE2ihgwQHGIxzKUdGIWQS-lSVyDLFXBUggmwqXNYZBIFKgOFGAiX51maMSt2yMm37rzNZ7YwNjSdYz2v_Qzrpa7Q6_-d4F_0c7XQSokuoBM4XAnU1VtrY6NnPhpblhhs1UbNUwmZlIMh79Cjb9TUVYy1db9rgOnPd-jLh4n-eofmrMMP_lr7hX_uLz4AI66Hkw</recordid><startdate>20201209</startdate><enddate>20201209</enddate><creator>Manzoor, Rashid</creator><creator>Eguchi, Nao</creator><creator>Yoshida, Reiko</creator><creator>Ozaki, Hiroichi</creator><creator>Kondoh, Tatsunari</creator><creator>Okuya, Kosuke</creator><creator>Miyamoto, Hiroko</creator><creator>Takada, Ayato</creator><general>American Society for Microbiology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7987-9884</orcidid></search><sort><creationdate>20201209</creationdate><title>A Novel Mechanism Underlying Antiviral Activity of an Influenza Virus M2-Specific Antibody</title><author>Manzoor, Rashid ; Eguchi, Nao ; Yoshida, Reiko ; Ozaki, Hiroichi ; Kondoh, Tatsunari ; Okuya, Kosuke ; Miyamoto, Hiroko ; Takada, Ayato</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c537t-7901a1faad9b5e6c7a1b55f4fda0b712a73031e4ffad85a3a7c1d363fbb8480e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Amino Acids</topic><topic>Animals</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal - metabolism</topic><topic>Antibodies, Viral - immunology</topic><topic>Antibodies, Viral - pharmacology</topic><topic>Antiviral Agents - immunology</topic><topic>Antiviral Agents - pharmacology</topic><topic>Dogs</topic><topic>HEK293 Cells</topic><topic>Hemagglutinin Glycoproteins, Influenza Virus - metabolism</topic><topic>Humans</topic><topic>Influenza A virus - drug effects</topic><topic>Influenza A virus - genetics</topic><topic>Influenza A virus - immunology</topic><topic>Madin Darby Canine Kidney Cells</topic><topic>Mutation</topic><topic>Protein Binding - drug effects</topic><topic>Species Specificity</topic><topic>Vaccines and Antiviral Agents</topic><topic>Viral Matrix Proteins - chemistry</topic><topic>Viral Matrix Proteins - genetics</topic><topic>Viral Matrix Proteins - immunology</topic><topic>Viral Matrix Proteins - metabolism</topic><topic>Virus Release - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Manzoor, Rashid</creatorcontrib><creatorcontrib>Eguchi, Nao</creatorcontrib><creatorcontrib>Yoshida, Reiko</creatorcontrib><creatorcontrib>Ozaki, Hiroichi</creatorcontrib><creatorcontrib>Kondoh, Tatsunari</creatorcontrib><creatorcontrib>Okuya, Kosuke</creatorcontrib><creatorcontrib>Miyamoto, Hiroko</creatorcontrib><creatorcontrib>Takada, Ayato</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Manzoor, Rashid</au><au>Eguchi, Nao</au><au>Yoshida, Reiko</au><au>Ozaki, Hiroichi</au><au>Kondoh, Tatsunari</au><au>Okuya, Kosuke</au><au>Miyamoto, Hiroko</au><au>Takada, Ayato</au><au>Heise, Mark T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Novel Mechanism Underlying Antiviral Activity of an Influenza Virus M2-Specific Antibody</atitle><jtitle>Journal of virology</jtitle><addtitle>J Virol</addtitle><date>2020-12-09</date><risdate>2020</risdate><volume>95</volume><issue>1</issue><issn>0022-538X</issn><eissn>1098-5514</eissn><abstract>Protective immunity against influenza A viruses (IAVs) generally depends on antibodies to the major envelope glycoprotein, hemagglutinin (HA), whose antigenicity is distinctive among IAV subtypes. On the other hand, the matrix 2 (M2) protein is antigenically highly conserved and has been studied as an attractive vaccine antigen to confer cross-protective immunity against multiple subtypes of IAVs. However, antiviral mechanisms of M2-specific antibodies are not fully understood. Here, we report the molecular basis of antiviral activity of an M2-specific monoclonal antibody (MAb), rM2ss23. We first found that rM2ss23 inhibited A/Aichi/2/1968 (H3N2) (Aichi) but not A/PR/8/1934 (H1N1) (PR8) replication. rM2ss23 altered the cell surface distribution of M2, likely by cross-linking the molecules, and interfered with the colocalization of HA and M2, resulting in reduced budding of progeny viruses. However, these effects were not observed for another strain, PR8, despite the binding capacity of rM2ss23 to PR8 M2. Interestingly, HA was also involved in the resistance of PR8 to rM2ss23. We also found that two amino acid residues at positions 54 and 57 in the M2 cytoplasmic tail were critical for the insensitivity of PR8 to rM2ss2. These findings suggest that the disruption of the M2-HA colocalization on infected cells and subsequent reduction of virus budding is one of the principal mechanisms of antiviral activity of M2-specific antibodies and that anti-M2 antibody-sensitive and -resistant IAVs have different properties in the interaction between M2 and HA.
Although the IAV HA is the major target of neutralizing antibodies, most of the antibodies are HA subtype specific, restricting the potential of HA-based vaccines. On the contrary, the IAV M2 protein has been studied as a vaccine antigen to confer cross-protective immunity against IAVs with multiple HA subtypes, since M2 is antigenically conserved. Although a number of studies highlight the protective role of anti-HA neutralizing and nonneutralizing antibodies, precise information on the molecular mechanism of action of M2-specific antibodies is still obscure. In this study, we found that an anti-M2 antibody interfered with the HA-M2 association, which is important for efficient budding of progeny virus particles from infected cells. The antiviral activity was IAV strain dependent despite the similar binding capacity of the antibody to M2, and, interestingly, HA was involved in susceptibility to the antibody. Our data provide a novel mechanism underlying antiviral activity of M2-specific antibodies.</abstract><cop>United States</cop><pub>American Society for Microbiology</pub><pmid>33055251</pmid><doi>10.1128/jvi.01277-20</doi><orcidid>https://orcid.org/0000-0002-7987-9884</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-538X |
ispartof | Journal of virology, 2020-12, Vol.95 (1) |
issn | 0022-538X 1098-5514 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7737731 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Amino Acids Animals Antibodies, Monoclonal - immunology Antibodies, Monoclonal - metabolism Antibodies, Viral - immunology Antibodies, Viral - pharmacology Antiviral Agents - immunology Antiviral Agents - pharmacology Dogs HEK293 Cells Hemagglutinin Glycoproteins, Influenza Virus - metabolism Humans Influenza A virus - drug effects Influenza A virus - genetics Influenza A virus - immunology Madin Darby Canine Kidney Cells Mutation Protein Binding - drug effects Species Specificity Vaccines and Antiviral Agents Viral Matrix Proteins - chemistry Viral Matrix Proteins - genetics Viral Matrix Proteins - immunology Viral Matrix Proteins - metabolism Virus Release - drug effects |
title | A Novel Mechanism Underlying Antiviral Activity of an Influenza Virus M2-Specific Antibody |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T16%3A14%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Novel%20Mechanism%20Underlying%20Antiviral%20Activity%20of%20an%20Influenza%20Virus%20M2-Specific%20Antibody&rft.jtitle=Journal%20of%20virology&rft.au=Manzoor,%20Rashid&rft.date=2020-12-09&rft.volume=95&rft.issue=1&rft.issn=0022-538X&rft.eissn=1098-5514&rft_id=info:doi/10.1128/jvi.01277-20&rft_dat=%3Cproquest_pubme%3E2451855692%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2451855692&rft_id=info:pmid/33055251&rfr_iscdi=true |